When you have early-stage follicular lymphoma, a slow-growing blood cancer, the main goal is to keep it from coming back for as long as possible. A long-term study followed 150 patients for over a decade and found that adding a drug regimen called R-CVP to standard radiation significantly improved the time patients lived without their cancer getting worse, compared to radiation alone or radiation with a different drug combo. The side effects from the added drugs were common but mostly temporary, with some patients experiencing moderate to severe reactions during treatment. While this is a strong signal from a randomized trial, it's important to remember the study shows an association, not a guaranteed cause-and-effect, and the full picture of long-term risks, like second cancers, is still being pieced together.
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphomaCan adding a drug cocktail to radiation help keep early lymphoma from returning?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider R-CVP after radiotherapy for selected early-stage follicular lymphoma patients based on improved PFS in long-term RCT data.
This multicenter randomized controlled trial enrolled 150 patients with early-stage (I-II) follicular lymphoma who had received involved-field radiotherapy (IFRT). Patients were randomized to receive IFRT alone, IFRT plus cyclophosphamide/vincristine/prednisolone (CVP), or IFRT plus rituximab-CVP (R-CVP). With a median follow-up of 11.3 years, the primary outcome of progression-free survival (PFS) was improved with IFRT plus R-CVP compared to IFRT alone or IFRT plus CVP (hazard ratio 0.36, p=0.01). Absolute PFS numbers were not reported.
Safety data showed short-term radiotherapy-related grade I-II toxicity occurred in over 90% of patients. For systemic therapy, worst acute toxicity included grade 1 (16 patients), grade 2 (31 patients), and grade 3 (20 patients), with 3 cases of grade 3 neuropathy. R-CVP and CVP were reported as equally toxic, and toxicity occurring more than 6 months after treatment was rare. Serious adverse events and discontinuation rates were not reported.
Key limitations include the absence of reported absolute PFS numbers, lack of detailed serious adverse event and discontinuation data, and no reported relationship between second malignancies and irradiated volumes or systemic therapy use. The study also found that indeterminate bone marrow aggregates did not worsen PFS.
Practice relevance is restrained: The improvement in PFS, reduced salvage therapy requirements, and prevention of histological transformation with R-CVP may outweigh its significant but transient toxicity in some patients. Those with indeterminate bone marrow lymphoid aggregates or non-contiguous stage II disease might merit consideration for curative-intent treatment approaches.
What this means for you:
Adding R-CVP drugs to radiation may delay lymphoma progression, but with significant short-term side effects. More on Follicular Lymphoma
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
View Original Abstract ↓
BACKGROUND AND PURPOSE: The recently-updated TROG 99.03/ALLGLow5 multicentre randomised controlled trial showed that long-term progression-free survival (PFS) in early-stage (I-II) follicular lymphoma (ESFL) after involved-field radiotherapy (IFRT) was dramatically improved by adjuvant rituximab-cyclophosphamide/vincristine/prednisolone (R-CVP) but not CVP. Secondary analyses are presented here.
MATERIALS AND METHODS: We analysed toxicity of RT and RT plus systemic therapy, outcomes for discontinuous stage II disease, second malignancy risks, prognostic impact of indeterminate bone marrow (BM) aggregates and the effect of rituximab on histological transformation. BM trephines from 55 patients from the pre-rituximab era were centrally reviewed.
RESULTS: As previously-reported, 150 patients were randomised to IFRT (n = 75) or IFRT plus systemic therapy (n = 75). After 11.3 years median follow-up, IFRT + R-CVP was associated with improved PFS compared to IFRT or IFRT + CVP (HR 0.36, p = 0.01). Short-term RT-related grade I-II toxicity occurred in >90%, but toxicity after >6 months was rare. Worst acute systemic therapy toxicity was G1 (16 patients, G2 31 and G3 20) with 3 grade 3 neuropathies. R-CVP and CVP were equally toxic. Only 2 of 5 patients with non-contiguous stage II relapsed. Of 64 relapsed patients, 39 commenced salvage therapies and 17 had second progressions. Second malignancies showed no relationship to irradiated-volumes or systemic therapy use. Indeterminate BM aggregates did not worsen PFS.
CONCLUSION: The improvement in PFS, reduced salvage therapy requirements, and prevention of histological transformation with R-CVP outweigh its significant but transient toxicity, supporting its justifiable use. Patients with indeterminate BM lymphoid aggregates or non-contiguous stage II FL may merit consideration for curative-intent treatment.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …